Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID 19 vaccine - Gamaleya National Research Center of Epidemiology and Microbiology

X
Drug Profile

COVID 19 vaccine - Gamaleya National Research Center of Epidemiology and Microbiology

Alternative Names: COVID-2019 vaccine - Gamaleya National Research Center of Epidemiology and Microbiology; Gam COVID Vak; Gam-COVID-Vac; single-dose Sputnik Light vaccine; Sputnik M; Sputnik V; Sputnik V vaccine; Sputnik-Light V vaccine

Latest Information Update: 11 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gamaleya Research Institute of Epidemiology and Microbiology
  • Developer AstraZeneca; Dr Reddys Laboratories; Gamaleya Research Institute of Epidemiology and Microbiology; Pure Health; R-Pharm; The Government of Serbia
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 05 Oct 2023 Gamaleya Research Institute of Epidemiology and Microbiology plans phase III trial for COVID 2019 infections (Prevention, In children, In adolescents ) in October 2023 (IM) (NCT06068556)
  • 05 Oct 2023 Gamaleya Research Institute of Epidemiology and Microbiology plans phase-III trial for COVID-2019 infection (prevention) in September 2023 (IM, Injection) (NCT06057025)
  • 04 Oct 2023 Gamaleya Research Institute of Epidemiology and Microbiology plans the phase III trial for COVID 2019 infections (Prevention) in an unknown location (IM) (NCT06068569)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top